SEP 10, 2019
In this interview from ASRS 2019, Dr. Peter Kertes discusses the rate of geographic atrophy (GA) in patients receiving treat-and-extend versus monthly ranibizumab for wet AMD. No significant variation in GA was noted at either 12 or 24 months, irrespective of the treatment protocol. The trial will continue to follow a subset of patients for 36 months.
Relevant Financial Disclosures: Drs. Kertes receives grant support from Genentech.